Description
The search for emerging markets is necessary part of growth strategy in IVD. This report provides an overview of developments in the in vitro diagnostics industry in the Middle East. This report provides an overview of developments in the in vitro diagnostics industry in the Middle East.
The countries covered are:
- Turkey
- United Arab Emirates (UAE)
The Middle East market for in vitro diagnostics is provided in U.S. dollars for the years 2017 – 2022. Also provided is company activities and market drivers.
The report covers six segments of the IVD market in the Middle East:
- Clinical Chemistry
- Immunoassays
- Microbiology
- Point of Care (POC)
- Histology
- Other
The next five to ten years will see moderate and gradual change in global in vitro diagnostic (IVD) product markets. While clinical lab medicine plays an integral role in healthcare and disease management, new testing is difficult to launch in a time of global economic instability and rising healthcare costs. On the supply side, labs are challenged to add new tests with little increase in financial and human resources.
IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care.
Many Middle Eastern countries, such as Saudi Arabia, have identified investment in healthcare infrastructure as a priority, the goal to expand healthcare beyond cities and into desert communities; today roughly 16% of the population is represented by rural areas of the country.
The region’s public sector has historically dominated the delivery of healthcare in the Middle East; however, recent activity from governments in the region approaching investors to expand the private sector in health care continues to be encouraging. This is a strategy to diversify and reduce some dependence on the petroleum industry as oil prices continue to be strained. Countries in the region need to create systems that empower the private sector to participate more deeply in the healthcare system. Growth in private sector participation will improve the quality of healthcare and access to it.
Some of the total IVD market growth derives from increased test usage in emerging countries. All of the major IVD companies have reported growth in Turkey and Saudi Arabia, considered two of the top seven emerging markets. These countries continue to invest in healthcare infrastructure and insurance coverage for a growing more affluent middle class.
This development requires increased investment in healthcare. This increased investment most often takes the form of government tenders, which remain a major source ofsupply for state-controlled labs and hospitals. Lifestyle change a more sedentary lifestyle resulting in rising obesity rates has brought about the emergence of “Western” diseases such as diabetes. There is growing demand in the region, therefore, for medical tests.
Table of Contents
1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
SIZE AND GROWTH OF THE MARKET
Figure 1-1: IVD in the Middle East, 2017-2022 CAGR 5.7%
2: MIDDLE EAST: REGIONAL OVERVIEW
POPULATION
Table 2-1: Elderly Dependency Ratio in Middle East and Other Select Countries, 2010 and 2050
Table 2-2: World Population: Mideast Region (Saudi Arabia, Turkey, Iran, Egypt, Iraq, United Arab Emirates, Israel, Jordan, Other Mideast) , 2005-2025 (million persons)
ECONOMIC OUTLOOK
Table 2-3: GDP: Mideast Region (Saudi Arabia, Turkey, Iran, Egypt, Iraq, United Arab Emirates, Israel, Jordan, Other Mideast) (billion US$)
MAJOR DISEASES AFFECTING THE MIDDLE EASTERN POPULATION
Cardiovascular Diseases
Cancer
Table: 2-4: The Most Frequent Cancers by Country of Middle East (%) As Reported by National Cancer Registry Programs, 2015
Diabetes
Table 2-5: People Living with Diabetes in Middle East Region and Projections 2045 (millions of people)
Middle Eastern Respiratory Syndrome (MERS)
Table 2-6: Epidemiological Characteristics of MERS Cases Reported Globally, (Dec 2012 – May 2013 through Dec 2017 – May 2018)
ARAB HEALTH CONGRESS
3: COUNTRY MARKET ANALYSIS
OVERVIEW
EGYPT IVD MARKET
Table 3-1: Egypt In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-2: Egypt – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Inhibitors
Market Participant Activity
IRAN IVD MARKET
Table 3-3: Iran In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-4: Iran – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Inhibitors
IRAQ IVD MARKET
Table 3-5: Iraq In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-6: Iraq – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Inhibitors
Market Participant Activity
ISRAEL IVD MARKET
Table 3-7: Israel In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-8: Israel – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Inhibitors
Market Participant Activity
JORDAN IVD MARKET
Table 3-9: Jordan In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-10: Jordan – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Participant Activity
SAUDI ARABIA IVD MARKET
Table 3-11: Saudi Arabia In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-12: Saudi Arabia – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Inhibitors
Market Participant Activity
TURKEY IVD MARKET
Table 3-13: Turkey In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-14: Turkey – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Inhibitors
Market Participant Activity
UNITED ARAB EMIRATES (UAE) IVD MARKET
Table 3-15: United Arab Emirates In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
Table 3-16: United Arab Emirates – POC Market Distribution, 2017-2022 (%) (POC Glucose, POC Other)
Market Drivers
Market Participant Activity
4: MARKET SUMMARY: TOTAL MIDEAST MARKET
SUMMARY
Table 4-1: Mideast In Vitro Diagnostic Sales by Market Segment, 2017-2022 (Clinical Chemistry, Immunoassay, Microbiology, POC, Histology, Other, Total) ($ millions)
CLINICAL CHEMISTRY MARKET
IMMUNOASSAY MARKET
MICROBIOLOGY MARKET
POINT-OF-CARE MARKET
HISTOLOGY MARKET
Table 4-2: Mideast In Vitro Diagnostic Sales by Country, 2017-2022 ($ millions) (Egypt, Iran, Iraq, Israel, Jordan, Saudi Arabia, Turkey, United Arab Emirates, Other Mideast, Total)
Figure 4-1: Mideast In Vitro Diagnostic Sales by Country, 2017-2022 – Eight Countries Generate more than 80% Market Value (Egypt, Iran, Iraq, Israel, Jordan, Saudi Arabia, Turkey, United Arab Emirates, Other Mideast)
